Literature DB >> 22182971

Bone cancer in 2011: Prevention and treatment of bone metastases.

Robert E Coleman1.   

Abstract

Bone-targeting treatments have transformed the quality of life of patients with metastatic bone disease. 2011 saw the emergence of denosumab—a RANK ligand-specific antibody—as a more-effective alternative treatment to bisphosphonates and of data on the use of bone-targeting treatments to prevent metastasis from breast and prostate cancers.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22182971     DOI： 10.1038/nrclinonc.2011.198

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  8 in total

1.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Authors:  David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

2.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Authors:  Michael Gnant; Brigitte Mlineritsch; Herbert Stoeger; Gero Luschin-Ebengreuth; Dietmar Heck; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Gunda Pristauz; Thomas Bauernhofer; Holger Eidtmann; Wolfgang Eiermann; Guenther Steger; Werner Kwasny; Peter Dubsky; Gerhard Hochreiner; Ernst-Pius Forsthuber; Christian Fesl; Richard Greil
Journal:  Lancet Oncol       Date:  2011-06-05       Impact factor: 41.316

3.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

4.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

5.  Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial.

Authors:  Matthew R Smith; Fred Saad; Robert Coleman; Neal Shore; Karim Fizazi; Bertrand Tombal; Kurt Miller; Paul Sieber; Lawrence Karsh; Ronaldo Damião; Teuvo L Tammela; Blair Egerdie; Hendrik Van Poppel; Joseph Chin; Juan Morote; Francisco Gómez-Veiga; Tomasz Borkowski; Zhishen Ye; Amy Kupic; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-11-15       Impact factor: 79.321

6.  Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

Authors:  Michael Gnant; Brigitte Mlineritsch; Walter Schippinger; Gero Luschin-Ebengreuth; Sabine Pöstlberger; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Vesna Bjelic-Radisic; Hellmut Samonigg; Christoph Tausch; Holger Eidtmann; Günther Steger; Werner Kwasny; Peter Dubsky; Michael Fridrik; Florian Fitzal; Michael Stierer; Ernst Rücklinger; Richard Greil; C Marth
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245

7.  Breast-cancer adjuvant therapy with zoledronic acid.

Authors:  Robert E Coleman; Helen Marshall; David Cameron; David Dodwell; Roger Burkinshaw; Maccon Keane; Miguel Gil; Stephen J Houston; Robert J Grieve; Peter J Barrett-Lee; Diana Ritchie; Julia Pugh; Claire Gaunt; Una Rea; Jennifer Peterson; Claire Davies; Victoria Hiley; Walter Gregory; Richard Bell
Journal:  N Engl J Med       Date:  2011-09-25       Impact factor: 91.245

8.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976
  8 in total
  34 in total

Review 1.  Bone metastasis and the metastatic niche.

Authors:  Guangwen Ren; Mark Esposito; Yibin Kang
Journal:  J Mol Med (Berl)       Date:  2015-08-15       Impact factor: 4.599

Review 2.  Dynamic live imaging of bone: opening a new era with 'bone histodynametry'.

Authors:  Masaru Ishii; Sayumi Fujimori; Takeshi Kaneko; Junichi Kikuta
Journal:  J Bone Miner Metab       Date:  2013-04-02       Impact factor: 2.626

Review 3.  Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?

Authors:  Karin Beelen; Wilbert Zwart; Sabine C Linn
Journal:  Nat Rev Clin Oncol       Date:  2012-07-24       Impact factor: 66.675

Review 4.  Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Authors:  Erika Vacchelli; Jonathan Pol; Norma Bloy; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jérôme Galon; Aurélien Marabelle; Holbrook Kohrt; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 5.  New therapeutic targets for cancer bone metastasis.

Authors:  Jing Y Krzeszinski; Yihong Wan
Journal:  Trends Pharmacol Sci       Date:  2015-05-09       Impact factor: 14.819

6.  Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation.

Authors:  Jessie S Jeon; Simone Bersini; Mara Gilardi; Gabriele Dubini; Joseph L Charest; Matteo Moretti; Roger D Kamm
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-18       Impact factor: 11.205

7.  Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab.

Authors:  Elisabet Cuyàs; Begoña Martin-Castillo; Joaquim Bosch-Barrera; Javier A Menendez
Journal:  Cell Cycle       Date:  2017-04-07       Impact factor: 4.534

8.  Peptide Decoration of Nanovehicles to Achieve Active Targeting and Pathology-Responsive Cellular Uptake for Bone Metastasis Chemotherapy.

Authors:  Xuli Wang; Ye Yang; Huizhen Jia; Wanjian Jia; Scott Miller; Beth Bowman; Jun Feng; Fenghuang Zhan
Journal:  Biomater Sci       Date:  2014-04-14       Impact factor: 6.843

9.  Lipid Osteoclastokines Regulate Breast Cancer Bone Metastasis.

Authors:  Jing Y Krzeszinski; Adam G Schwaid; Wing Yin Cheng; Zixue Jin; Zachary R Gallegos; Alan Saghatelian; Yihong Wan
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

Review 10.  Role of RANKL/RANK in primary and secondary breast cancer.

Authors:  Toshiyuki Yoneda; Soichi Tanaka; Kenji Hata
Journal:  World J Orthop       Date:  2013-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.